Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

NCT03281538 PHASE3 COMPLETED Results posted

This is an open-label multicenter, long-term extension safety study to evaluate the safety of IV CR845 administered after each dialysis session over a Treatment Period of up to 52 weeks.

Details

Lead sponsor	Cara Therapeutics, Inc.
Phase	PHASE3
Status	COMPLETED
Enrolment	288
Start date	Mon Aug 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Feb 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Uremic Pruritus

Interventions

• CR845

Countries

Puerto Rico, United States